Session Information
Date: Thursday, June 8, 2017
Session Title: Dystonia
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To carry out a cost-utility analysis for IncoBTX administered with flexible treatment intervals compared to OnaBTX in the management of BL and CD from the payer perspective in the province of Ontario, Canada.
Background: IncobotulinumtoxinA (IncoBTX) and onabotulinumtoxinA (OnaBTX) have marketing authorization in Canada for the treatment of blepharospasm (BL) and cervical dystonia (CD). IncoBTX is the only botulinum toxin in Canada with marketing authorization for administration at flexible intervals between 6-20 weeks based on the patient needs clinically confirmed.
Methods: A Markov state transition model was developed to estimate costs (CDN$, 2016) and benefits (Quality Adjusted Life Years, QALY) of the management of BL and CD with IncoBTX administered at flexible intervals (6 to 20 weeks) vs OnaBTX (minimum 12, maximum 20 weeks); a 5-year horizon time was used. It was assumed that patients experience a re-emergence of symptoms after toxin treatment effect wanes. Utilities were extracted from a published study in patients with focal dystonia. Costs (drugs acquisition and administration) were based on Canadian public databases. Deterministic and probabilistic sensitivity analyses were performed.
Results: In the management of BL, IncoBTX was a dominant strategy versus OnaBTX, with higher effectiveness (2.9023 vs 2.8759 QALYs) and lower cost (C$ 9,330 vs C$ 9,348). In the management of CD, IncoBTX was a dominant strategy versus OnaBTX, with higher effectiveness (3.3138 vs 3.2556 QALYs) and lower cost (C$ 16,074 vs C$ 16,932). Patients treated with IncoBTX flexible intervals had nearly half the number of symptomatic weeks for both BL (23.28 vs 45.40 weeks) and CD (22.29 vs 43.63 weeks).
Conclusions: The treatment of BL and CD with IncoBTX at flexible intervals determined by the patient needs clinically confirmed is an efficient therapeutic alternative compared to the administration of OnaBTX in Ontario, Canada. Patients treated at flexible intervals had fewer symptomatic weeks while accruing less cost compared to the patients treated at minimum 12-weeks intervals.
To cite this abstract in AMA style:
M.-E. Gendron, M.-E. Gendron, R. Kazerooni. Cost-utility analysis of flexible interval incobotulinumtoxinA versus onabotulinumtoxinA in the management of blepharospasm and cervical dystonia in Ontario, Canada. [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/cost-utility-analysis-of-flexible-interval-incobotulinumtoxina-versus-onabotulinumtoxina-in-the-management-of-blepharospasm-and-cervical-dystonia-in-ontario-canada/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/cost-utility-analysis-of-flexible-interval-incobotulinumtoxina-versus-onabotulinumtoxina-in-the-management-of-blepharospasm-and-cervical-dystonia-in-ontario-canada/